Grant of options under Long Term Incentive Plan

Horizon Discovery Group plc

("Horizon" or the "Company")

Grant of options under Long Term Incentive Plan

Cambridge, UK, 15 October 2015: Horizon Discovery Group plc (LSE: HZD), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, announces that, pursuant to the contractual annual grant of options under the Company's LTIP plan as disclosed in the Company's AIM Admission Document dated 27 March 2014, the following LTIP options over the Company's ordinary shares of 1 penny each ("Ordinary Shares") were granted today to the following Directors of the Company: 

The options granted have a vesting period of three years and have an exercise price of £1.51. There are no performance conditions. The LTIP options granted are equivalent to 0.3 per cent. of the Company's existing issued share capital. Under the Company's LTIP plan, options will be granted to participants on an annual basis.

ENDS

For further information from Horizon Discovery Group plc, please contact:

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0)7787 502 947

Email: [email protected]

Consilium Strategic Communications (Financial Media and Investor Relations)

Amber Fennell / Jessica Hodgson / Matthew Neal / Laura Thornton

Tel: +44 (0) 20 3709 5701

Email: [email protected]

Panmure Gordon & Co. (NOMAD and Broker)

Corporate Finance: Freddy Crossley / Fabien Holler / Duncan Monteith

Broking: Tom Salvesen

Tel: +44 20 7886 2500

Notes for Editors

About Horizon Discovery Group plc

Horizon is a revenue-generating life science group supplying research tools to organisations engaged in genomics research and the development of personalised medicines. Horizon has a diverse and international customer base of over 1,000 organisations across nearly 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Group supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.

Horizon's core capabilities are built around its proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon offers circa 16,500 products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These 'patients-in-a-test-tube' are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

In addition, Horizon provides custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, and contract research and custom screening services.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD", for further information please visit: www.horizondiscovery.com.